Regulatory Considerations for Novel Gene Therapy Products: A Review of the Process Leading to the First Clinical Lentiviral Vector
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
This review is intended to exemplify the roles and responsibilities of the two agencies under the Department of Health and Human Services, the National Institutes of Health and the Food and Drug Administration, that have oversight for human gene transfer clinical protocols, as seen through our experience of bringing a first-in-its-class lentiviral vector to clinical trials. In response to the changing circumstances in gene therapy research between 1999 and 2002, the concerns of these agencies regarding gene therapy have been evolving. This review provides an overview of the major safety concerns regarding insertional oncogenesis, the generation of a replication- competent lentivirus (RCL), and vector mobilization thought to be related to lentiviral vectors, which had to be addressed during the regulatory review process before initiating the clinical trial. Specific monitoring assays to address these concerns were established to test for RCL generation, vector mobilization, persistence of vector-modified cells, and abnormal clonal expansion of modified cells. We hope to provide a basic understanding and appreciation of the regulatory process and major safety concerns, toward providing useful insight to those presently embarking on the development of clinical application of lentiviral vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Virus treatment questioned after gene therapy death
Lehrman, S. (1999) · Nature · doi:10.1038/43977 · Cited by 576 · cited 5×
“These concerns arose after the death in 1999 of a patient undergoing a University of Pennsylvania gene therapy trial for ornithine transcarboxylase deficiency (OTCD) (Lehrman, 1999).”
InfluentialHelper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer
Donahue, R. E., Kessler, S. W., Bodine, D., McDonagh, K., Dunbar, C., Goodman, S., Agricola, B., Byrne, E., Raffeld, M., & Moen, R. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.4.1125 · Cited by 532
Anson, D. S. (2004) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-2-9 · Cited by 154
Cited by
Altering the Tropism of Lentiviral Vectors through Pseudotyping
Cronin, J., Zhang, X.-Y., & Reiser, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054546224 · Cited by 536
Gene transfer in humans using a conditionally replicating lentiviral vector
Levine, B. L., Humeau, L. M., Boyer, J., MacGregor, R.-R., Rebello, T., Lu, X., Binder, G. K., Slepushkin, V., Lemiale, F., Mascola, J. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608138103 · Cited by 501
Self-citationGene delivery by lentivirus vectors
Cockrell, A. S., & Kafri, T. (2007) · Molecular Biotechnology · doi:10.1007/s12033-007-0010-8 · Cited by 355
Recent Advances in Lentiviral Vector Development and Applications
Mátrai, J., Chuah, M. K., & VandenDriessche, T. (2010) · Molecular Therapy · doi:10.1038/mt.2009.319 · Cited by 347
Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential
Escors, D., & Breckpot, K. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0063-4 · Cited by 344
“In fact, in the first approved human clinical trial using lentivectors for the treatment of HIV, no abnormal cell expansion or enrichment of integration sites near proto-oncogenes has been detected so far (Manilla et al. 2005; Themis et al. 2005).”
Metadata
- Authors
- Manilla, P., Rebello, T., Afable, C., Lu, X., Slepushkin, V., Humeau, L. M., Schonely, K., Ni, Y., Binder, G. K., Levine, B. L., Macgregor, R.-R., June, C. H., & Dropulic, B.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2005-01
- Volume
- 16
- Issue
- 1
- Pages
- 17-25
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W1985095994
- Cited by
- 147
- References
- 3
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.